ApoImmune, Large Scale Biology deal

LSBC will produce two of ApoImmune’s polypeptides for use as cancer vaccine adjuvants. The deal combines LSBC’s GeneWare manufacturing technology with ProtEx cancer cell targeting technology from Apo...